Desmethylsertraline
Source: Wikipedia, the free encyclopedia.
Chemical compound
 | |
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Elimination half-life | 66 hours |
| Excretion | urine |
| Identifiers | |
| |
JSmol) | |
| |
Desmethylsertraline (DMS), also known as norsertraline, is an
serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI), with about 5.5-fold preference for inhibiting serotonin reuptake relative to catecholamine reuptake.[2]
attention-deficit disorder, and eating disorders
, but has not been approved or marketed for any indication.
See also
- Desmethylcitalopram
- Desmethylvenlafaxine
- Didesmethylcitalopram
- Indatraline
- Lometraline
- Norfluoxetine
- Tametraline
References
| ||
|---|---|---|
SNRIs Tooltip Serotonin–norepinephrine reuptake inhibitors | ||
NRIs Tooltip Norepinephrine reuptake inhibitors | ||
NDRIs Tooltip Norepinephrine–dopamine reuptake inhibitors | ||
NaSSAs Tooltip Noradrenergic and specific serotonergic antidepressants | ||
SARIs Tooltip Serotonin antagonist and reuptake inhibitors | ||
SMS Tooltip Serotonin modulator and stimulators | ||
| Others |
| |
TCAs Tooltip Tricyclic antidepressants |
| |
|---|---|---|
TeCAs Tooltip Tetracyclic antidepressants | ||
| Others | ||
| |||||||
|
Miscellaneous | |
|---|---|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III